Administration of an MRA dose of ≥12.5 mg/d post-TEER (ie, any doses of MRA) was independently associated with a reduced risk of the primary outcome, with an HR of 0.83 (95% CI: 0.69-0.99; P = 0.046), adjusted for predefined potential confounders including age, atrial fibrillation, estimated glomerular filtration rate, use of beta-blockers post-TEER, use of renin-angiotensin system inhibitors post-TEER, and use of diuretic agents post-TEER. The gene discussed is REN; the disease is atrial fibrillation.